Out­come Health ex­ec­u­tives con­vict­ed in $1B phar­ma ad­ver­tis­ing and in­vest­ing fraud scheme

3 years ago
Pharma
Marketing

FDA may need to 'get cre­ative' if abor­tion pill ap­proval pulled this week

3 years ago
FDA+

Biotech ex­ecs say mifepri­s­tone de­ci­sion would 'u­pend' FDA's new drug ap­pli­ca­tion process

3 years ago
Pharma
FDA+

Ae­glea Bio­Ther­a­peu­tics to re­duce head­count to 10, seek strate­gic al­ter­na­tives

3 years ago
People

Amid dra­ma, Cutera toss­es out CEO and chair, ap­points re­place­ments

3 years ago
People

As­traZeneca ends dai­ly GLP-1/glucagon tri­als in switch to week­ly in­jec­tion op­tion for NASH, oth­er in­di­ca­tions

3 years ago
R&D
Pharma

Bio­gen opts in­to De­nali Alzheimer's pro­gram tar­get­ing amy­loid be­ta plaque

3 years ago
Deals

Treg play­er Gen­tiBio turns to lay­offs; Cen­tu­ry Ther­a­peu­tics CEO de­parts

3 years ago
News Briefing

Take­da tak­ing mag­ni­fy­ing glass to non-vi­ral gene ther­a­py pro­grams as Carmine pact ends

3 years ago
R&D
Cell/Gene Tx

Astel­las takes $435M+ write­down on Evren­zo, hear­ing loss can­di­date and T cell ther­a­py deal

3 years ago
Deals
Pharma

Mer­ck KGaA's BTK in­hibitor hit by par­tial clin­i­cal hold over safe­ty con­cern, but PhI­II read­out un­af­fect­ed

3 years ago
R&D
FDA+

Sci­ence-whiz twins backed by a16z bring Func­tion On­col­o­gy out of stealth

3 years ago
Financing
R&D

No­vo Nordisk taps in­to Cana­di­an biotech’s cell ther­a­pies for di­a­betes and obe­si­ty in deal worth up to $2.6B

3 years ago
Startups
Deals

SPAC led by Bio­gen chair­man Pa­padopou­los can't find a deal and will liq­ui­date

3 years ago
Financing
Deals

Mod­er­na notch­es a win in long-run­ning Ar­bu­tus patent fight

3 years ago
Pharma
Law

FDA hands warn­ing let­ters to US, In­di­an man­u­fac­tur­ers over glyc­erin con­t­a­m­i­na­tion

3 years ago
FDA+
Manufacturing

Bris­tol My­ers, Foun­da­tion Med­i­cine ex­pand col­lab­o­ra­tion to ex-Turn­ing Point can­cer drug

3 years ago
Deals
Pharma

How ARPA-H's new hub-and-spoke mod­el will cre­ate a na­tion­wide re­search net­work

3 years ago
R&D
Pharma

Four years lat­er, FDA fi­nal­izes guid­ance on risk-based mon­i­tor­ing of clin­i­cal tri­als

3 years ago
R&D
FDA+

Preprint man­date? BioRx­iv and medRx­iv founders call on White House to en­sure ear­ly ac­cess to gov­ern­ment-fund­ed ...

3 years ago
R&D

Lat­est ex­ten­sion of Al­ler­gan Aes­thet­ics-spon­sored do­cuseries goes ‘Be­yond the Be­fore & Af­ter’ 

3 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Ab­b­Vie, Hori­zon, Mer­ck make cut for 100 best US work­places; Lil­ly taps new chief brand of­fi­cer

3 years ago
Pharma
Marketing

As­traZeneca launch­es men­tal health hub for blood can­cer pa­tients and care­givers

3 years ago
Pharma
Marketing

Up­dat­ed: Mod­er­na: Not enough flu cas­es in PhI­II tri­al yet to tell ef­fi­ca­cy

3 years ago
R&D
First page Previous page 359360361362363364365 Next page Last page
A service from the Financial Times